212 related articles for article (PubMed ID: 35954431)
1. Conventional Therapeutics in BPDCN Patients-Do They Still Have a Place in the Era of Targeted Therapies?
Poussard M; Angelot-Delettre F; Deconinck E
Cancers (Basel); 2022 Aug; 14(15):. PubMed ID: 35954431
[TBL] [Abstract][Full Text] [Related]
2. Novel Therapeutic Approaches in Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): Era of Targeted Therapy.
Wilson NR; Konopleva M; Khoury JD; Pemmaraju N
Clin Lymphoma Myeloma Leuk; 2021 Nov; 21(11):734-740. PubMed ID: 34226167
[TBL] [Abstract][Full Text] [Related]
3. Blastic plasmacytoid dendritic cell neoplasm (BPDCN): A promising future in the era of targeted therapeutics.
Adimora IJ; Wilson NR; Pemmaraju N
Cancer; 2022 Aug; 128(16):3019-3026. PubMed ID: 35726525
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic Approaches for Blastic Plasmacytoid Dendritic Cell Neoplasm: Allogeneic Hematopoietic Cell Transplantation and Novel Therapies.
Kharfan-Dabaja MA; Pemmaraju N; Mohty M
Clin Hematol Int; 2019 Mar; 1(1):2-9. PubMed ID: 34595405
[TBL] [Abstract][Full Text] [Related]
5. Blastic plasmacytoid dendritic cell neoplasm: update on molecular biology, diagnosis, and therapy.
Riaz W; Zhang L; Horna P; Sokol L
Cancer Control; 2014 Oct; 21(4):279-89. PubMed ID: 25310209
[TBL] [Abstract][Full Text] [Related]
6. Blastic plasmacytoid dendritic cell neoplasm: update on therapy especially novel agents.
Wang S; Wang X; Liu M; Bai O
Ann Hematol; 2018 Apr; 97(4):563-572. PubMed ID: 29455234
[TBL] [Abstract][Full Text] [Related]
7. Recent developments in the treatment of blastic plasmacytoid dendritic cell neoplasm.
Economides MP; Konopleva M; Pemmaraju N
Ther Adv Hematol; 2019; 10():2040620719874733. PubMed ID: 31579499
[TBL] [Abstract][Full Text] [Related]
8. Hyper-CVAD combined with Venetoclax for relapsed pediatric blastic plasmacytoid dendritic cell neoplasm (BPDCN): A case report and literature review.
Abla D; Abboud MR; Noun D; Tarek N; Pemmaraju N
Leuk Res Rep; 2022; 17():100313. PubMed ID: 35462725
[TBL] [Abstract][Full Text] [Related]
9. Hematopoietic Cell Transplant for Blastic Plasmacytoid Dendritic Cell Neoplasm.
Kharfan-Dabaja MA; Cherry M
Hematol Oncol Clin North Am; 2020 Jun; 34(3):621-629. PubMed ID: 32336425
[TBL] [Abstract][Full Text] [Related]
10. Multicenter analysis of outcomes in blastic plasmacytoid dendritic cell neoplasm offers a pretargeted therapy benchmark.
Taylor J; Haddadin M; Upadhyay VA; Grussie E; Mehta-Shah N; Brunner AM; Louissaint A; Lovitch SB; Dogan A; Fathi AT; Stone RM; Tallman MS; Rampal RK; Neuberg DS; Stevenson KE; Horwitz SM; Lane AA
Blood; 2019 Aug; 134(8):678-687. PubMed ID: 31243042
[TBL] [Abstract][Full Text] [Related]
11. Updates in Novel Therapies for Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN).
Economides MP; Rizzieri D; Pemmaraju N
Curr Hematol Malig Rep; 2019 Dec; 14(6):515-522. PubMed ID: 31853773
[TBL] [Abstract][Full Text] [Related]
12. Blastic Plasmacytoid Dendritic Cell Neoplasm: Single Center Experience on a Rare Hematological Malignancy.
Narli Ozdemir Z; Cengiz Seval G; Sahin U; Uslu A; Gunduz M; Civriz Bozdag S; Toprak SK; Kurt Yuksel M; Topcuoglu P; Kuzu I; Ozcan M; Gurman G; Ilhan O
Indian J Hematol Blood Transfus; 2021 Jan; 37(1):67-75. PubMed ID: 33707837
[TBL] [Abstract][Full Text] [Related]
13. Unique presentation of blastic plasmacytoid dendritic cell neoplasm: a single-center experience and literature review.
Paluri R; Nabell L; Borak S; Peker D
Hematol Oncol; 2015 Dec; 33(4):206-11. PubMed ID: 24850172
[TBL] [Abstract][Full Text] [Related]
14. The advances in therapy of blastic plasmacytoid dendritic cell neoplasm.
Kerr D; Sokol L
Expert Opin Investig Drugs; 2018 Sep; 27(9):733-739. PubMed ID: 30118336
[TBL] [Abstract][Full Text] [Related]
15. Clinical Insights into the Management of Blastic Plasmacytoid Dendritic Cell Neoplasm.
Zhang Y; Sokol L
Cancer Manag Res; 2022; 14():2107-2117. PubMed ID: 35789956
[TBL] [Abstract][Full Text] [Related]
16. Blastic Plasmacytoid Dendritic Cell Neoplasm.
Jain A; Sweet K
J Natl Compr Canc Netw; 2023 May; 21(5):515-521. PubMed ID: 37156483
[TBL] [Abstract][Full Text] [Related]
17. Targeting CD123 in blastic plasmacytoid dendritic cell neoplasm using allogeneic anti-CD123 CAR T cells.
Cai T; Gouble A; Black KL; Skwarska A; Naqvi AS; Taylor D; Zhao M; Yuan Q; Sugita M; Zhang Q; Galetto R; Filipe S; Cavazos A; Han L; Kuruvilla V; Ma H; Weng C; Liu CG; Liu X; Konoplev S; Gu J; Tang G; Su X; Al-Atrash G; Ciurea S; Neelapu SS; Lane AA; Kantarjian H; Guzman ML; Pemmaraju N; Smith J; Thomas-Tikhonenko A; Konopleva M
Nat Commun; 2022 Apr; 13(1):2228. PubMed ID: 35484100
[TBL] [Abstract][Full Text] [Related]
18. Effective Treatment of a Childhood Blastic Plasmacytoid Dendritic Cell Neoplasm with a Cutaneous Tumor Alone by Stem Cell Transplantation with Reduced Intensity Conditioning.
Shimomura M; Asano T; Furue A; Miki M; Sera Y; Kawaguchi H; Nakamura K; Kobayashi M
Indian J Hematol Blood Transfus; 2016 Jun; 32(Suppl 1):26-31. PubMed ID: 27408349
[TBL] [Abstract][Full Text] [Related]
19. Blastic plasmacytoid dendritic cell neoplasm: challenges and future prospects.
Trottier AM; Cerquozzi S; Owen CJ
Blood Lymphat Cancer; 2017; 7():85-93. PubMed ID: 31360087
[TBL] [Abstract][Full Text] [Related]
20. Treatment of blastic plasmacytoid dendritic cell neoplasm.
Sullivan JM; Rizzieri DA
Hematology Am Soc Hematol Educ Program; 2016 Dec; 2016(1):16-23. PubMed ID: 27913457
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
